The sensitivity of malignant tissues to T cell-based cancer immunotherapies is dependent on the presence of targetable HLA class I ligands on the tumor cell surface. Peptide intrinsic factors, such as
The HLA-I-eluted immunopeptidome of the GR lymphoblastoid cell line (GR-LCL) was analyzed by a two-dimensional (2D) peptide prefractionation strategy followed by a hybrid peptide fragmentation method
Considering the well established role of nonclassical HLA-G class I molecules in inhibiting natural killer (NK) cell function, the consequence of abnormal HLA-G expression in malignant cells should be
For each region, HLA types for which there are reported and predicted epitopes in the Los Alamos HIV Immunology Database (http://www.hiv.lanl.gov/content/sequence/ELF/epitope_analyzer.html) are listed